#!/usr/bin/env node
/**
 * BIO-451: Expand Saudi, Kuwait, Egypt country pages to 2000+ words
 * Reads marketResearchCountryContent.ts and expands the specified country entries
 */

import { readFileSync, writeFileSync } from 'fs';
import { fileURLToPath } from 'url';
import { dirname, join } from 'path';

const __filename = fileURLToPath(import.meta.url);
const __dirname = dirname(__filename);
const rootDir = join(__dirname, '..');

const contentPath = join(rootDir, 'src/data/marketResearchCountryContent.ts');

// Read the file
let content = readFileSync(contentPath, 'utf-8');

// Expanded intro for Saudi
const saudiIntroExpanded = `'BioNixus provides market research Saudi support for teams that need clear evidence from physicians, payers, and institutional stakeholders across the Kingdom. This page targets "market research Saudi" search intent and links to <a href="/healthcare-market-research/saudi-arabia">KSA healthcare market research</a>, <a href="/market-research-saudi-arabia-pharmaceutical">pharmaceutical market research in Saudi Arabia</a>, and <a href="/healthcare-market-research">healthcare hub resources</a> so planners capture both keyword variants with one coherent evidence story. Market research Saudi engagements reflect the Kingdom\\'s unique combination of centralized regulatory authority through SFDA (sfda.gov.sa), procurement systems via NUPCO, and rapidly evolving health economics requirements including the mandatory Economic Evaluation System (EES) effective from 1 July 2025. Teams operating in this market need research that speaks directly to how Saudi physicians make prescribing decisions under resource constraints, how hospital committees evaluate new therapies against local budget impact thresholds, and how access pathways differ between referral centers and primary care networks. Our programs are designed to generate decision-ready intelligence that aligns with both clinical realities and institutional evidence expectations across the Kingdom\\'s public and private healthcare sectors. When planning market research Saudi initiatives, sponsors must account for the Kingdom\\'s position as the single largest pharmaceutical market in the GCC—representing close to two-fifths of the roughly $23.7 billion Gulf pharmaceutical market (BioNixus market analysis, 2024)—and the corresponding competitive intensity that scale attracts. Every major global player targets Saudi Arabia early in their regional sequence, which means your evidence must differentiate not just on molecule but on access narrative, stakeholder prioritization, and institutional credibility. BioNixus designs market research Saudi programs to address those competitive realities with <a href="/blog/sfda-drug-registration-guide">SFDA-aligned evidence frameworks</a>, NUPCO tender intelligence, and payer-validated positioning that stands up under committee scrutiny across Riyadh, Jeddah, Dammam, and Mecca hospital networks.',`;

// Expanded regulatory for Saudi
const saudiRegulatoryExpanded = `    regulatory: {
      heading: 'Why Saudi regulatory context changes your research plan',
      paragraphs: [
        'Market research Saudi engagements should treat SFDA requirements and local evidence standards as part of the insight architecture—not a post-hoc checklist. That includes understanding which claims physicians trust and which documents committees request. The Saudi Food and Drug Authority (SFDA) at sfda.gov.sa sets registration, labeling, and pharmacovigilance expectations that influence how clinical narratives are framed and what comparators are considered credible. Programs that ignore SFDA precedent risk generating insights that cannot be operationalized within the Kingdom\\'s regulatory reality.',
        'Institutional buying and centralized procurement through NUPCO influence many brands, especially hospital-administered biologics and specialty therapies. Saudi programs map where decisions are clinical versus economic, and how long listing or tender steps typically run for comparable therapies. NUPCO tender cycles, committee composition, and pricing benchmarks vary by therapeutic category; market research Saudi modules quantify how those dynamics affect launch timelines and revenue ramp assumptions for Saudi-first or Saudi-weighted GCC strategies.',
        'The SFDA Economic Evaluation System (EES), mandatory from 1 July 2025, requires cost-effectiveness and budget impact submissions for reimbursement consideration. This policy shift elevates the importance of health economics evidence generation in parallel with traditional market research. BioNixus coordinates market research Saudi fieldwork with <a href="/heor-consulting-saudi-arabia">HEOR consulting in Saudi Arabia</a> so economic models reflect real-world treatment patterns, physician-stated adoption curves, and institutional budget constraints validated through stakeholder interviews rather than imported assumptions.',
        'Localization policies and workforce nationalization (Saudization) affect partnership choices, distributor selection, and medical affairs team structures. Market research Saudi studies test how local manufacturing partnerships, technology transfer commitments, or domestic clinical trial investments change stakeholder perceptions and access speed. These strategic variables can shift competitive positioning as much as clinical differentiation, which is why research modules often include scenarios that quantify their impact on prescriber and payer attitudes.',
      ],
    },`;

// Expanded market structure for Saudi
const saudiMarketStructureExpanded = `    marketStructure: {
      heading: 'Saudi market structure insights',
      paragraphs: [
        'At roughly $9.4 billion in 2024 and a projected $11.7 billion by 2033 (BioNixus market analysis, 2024), Saudi Arabia is the single largest pharmaceutical market in the Gulf. Care is delivered through a mix of Ministry of Health referral networks, military and university hospitals, and fast-growing private capacity concentrated in major urban centers. Market research Saudi samples should mirror where your patients and prescribers actually interact with the category — not a national average that masks regional variation. A Riyadh oncology program looks nothing like a Tabuk primary care launch, and conflating the two produces misleading forecasts.',
        'Specialty therapies often depend on a small set of expert centers with specific formularies, procurement committees, and evidence expectations; mass-market brands may rely on primary care clinic networks and retail pharmacy volume where out-of-pocket and insurance coverage patterns differ substantially. Segmentation logic must match the commercial model. Market research Saudi programs define addressable patient populations by care setting, payer mix, and physician specialization so that sizing translates directly into account targeting and resource allocation decisions.',
        'Competitive sets in Saudi Arabia can differ from UAE or Egypt even for the same molecule — and Saudi alone makes up close to two-fifths of the roughly $23.7 billion GCC pharmaceutical market (BioNixus market analysis, 2024). We benchmark switch risk, messaging resonance, and detailing effectiveness using Saudi-validated analogues from prior launches in the same therapeutic class rather than importing Gulf-wide assumptions that ignore Kingdom-specific prescribing cultures, payer policies, and institutional relationships. Competitive intelligence modules track not just which brands hold share but why: clinical trust, medical affairs investment, pricing strategy, or distributor strength. Those "why" answers inform defensive plays and help prioritize where to challenge incumbents versus where to co-exist.',
        'The Kingdom\\'s Vision 2030 healthcare transformation agenda is expanding capacity, digitalizing patient records, and increasing private sector participation. These structural shifts create both opportunity and complexity: new hospitals and clinics open addressable accounts, but also fragment decision-making and introduce new payer models. Market research Saudi studies quantify how these changes affect market access timelines, key account identification, and the relative weight of MOH versus private institutional strategies. Programs that ignore the Vision 2030 roadmap risk planning for a market structure that no longer exists by the time of launch.',
      ],
    },`;

// Now apply the replacements
// Replace saudi intro
content = content.replace(
  /saudi: \{[\s\S]*?intro:\s*'BioNixus provides market research Saudi support[^']*',/,
  (match) => {
    const before = match.substring(0, match.indexOf("intro:") + 6);
    return before + "\n      " + saudiIntroExpanded;
  }
);

// Replace saudi regulatory (find and replace the whole regulatory object)
content = content.replace(
  /(\s+)regulatory: \{[\s\S]*?heading: 'Why Saudi regulatory context[^}]*\},[\s\S]*?paragraphs: \[[\s\S]*?\],[\s\S]*?\},/,
  saudiRegulatoryExpanded
);

// Replace saudi market structure
content = content.replace(
  /(\s+)marketStructure: \{[\s\S]*?heading: 'Saudi market structure insights'[\s\S]*?paragraphs: \[[\s\S]*?\],[\s\S]*?\},/,
  saudiMarketStructureExpanded
);

// Expanded intro for Kuwait
const kuwaitIntroExpanded = `'BioNixus builds market research Kuwait studies for teams needing decision-ready intelligence in one of the GCC\\'s concentrated, high-spend healthcare markets. Programs reflect MOH and private channel dynamics, distributor-led access, and bilingual reporting for regional leadership. Market research Kuwait engagements address the unique characteristics of a smaller but strategically important Gulf market where prescriber networks are concentrated, institutional procurement dominates specialty access, and pricing sensitivity runs higher than in neighboring Saudi Arabia or UAE. Kuwait\\'s Ministry of Health formulary processes, Central Agency for Public Tenders procurement cycles, and private insurance dynamics create distinct access pathways that require Kuwait-specific research design rather than generic GCC templates. BioNixus designs market research Kuwait programs to capture how physicians, pharmacists, hospital committees, and payers evaluate new therapies within Kuwait\\'s resource-constrained but high-quality healthcare system. With the pharmaceutical market forecast to reach about $2.9 billion by 2027, growing around 3.5% annually (BioNixus market analysis, 2024), Kuwait represents a meaningful revenue opportunity within the roughly $23.7 billion GCC pharmaceutical market (BioNixus market analysis, 2024)—especially for brands that can navigate its concentrated stakeholder landscape effectively. Our programs link to <a href="/healthcare-market-research/kuwait">healthcare market research in Kuwait</a>, <a href="/kuwait-market-access-research">Kuwait market access research</a>, and <a href="/pharmaceutical-companies-kuwait">top pharmaceutical companies in Kuwait</a> to support both commercial intelligence and partnership due diligence.',`;

// Expanded regulatory for Kuwait  
const kuwaitRegulatoryExpanded = `    regulatory: {
      heading: 'Kuwait regulatory and access context',
      paragraphs: [
        'Kuwait market research should reflect Ministry of Health formulary processes, hospital drug committees, and private insurance rules that can diverge from UAE or Saudi pathways even within the GCC framework. The MOH and Central Agency for Public Tenders drive institutional procurement for the majority of hospital-administered therapies, which means understanding committee composition, evaluation criteria, and tender timing is as important as clinical evidence generation. Market research Kuwait modules map who makes formulary recommendations, what documentation they request, and how long approval cycles typically run for comparable therapeutic classes.',
        'Distributor and marketing authorization holder structures in Kuwait affect who owns access conversations and how medical affairs support is delivered. Unlike markets with direct pharmaceutical company presence, Kuwait often relies on exclusive distributor partnerships that control market entry, pricing negotiations, and stakeholder engagement. Market research Kuwait studies map commercial versus medical touchpoints accordingly, identifying which relationships are distributor-led and where direct engagement with institutions or key opinion leaders is possible or expected.',
        'Pricing and reimbursement sensitivity is high relative to market size; research modules often include willingness-to-pay proxies, analogues from comparable Gulf markets, and budget impact scenarios that reflect Kuwait\\'s public health financing constraints. When benchmarking Kuwait pricing against the roughly $23.7 billion GCC pharmaceutical market (BioNixus market analysis, 2024), teams must account for differences in income levels, insurance penetration, and institutional purchasing power. Market research Kuwait programs quantify how price premium tolerance compares to UAE or Saudi Arabia, and what clinical or access value propositions justify higher acquisition costs to committees operating under budget pressure.',
        'Localization expectations and workforce policies influence partnership selection and stakeholder engagement strategies. Market research Kuwait fieldwork tests how local partnerships, Arabic medical content, and Kuwait-based clinical trial participation affect prescriber and payer perceptions. These variables can determine whether a brand is viewed as committed to the Kuwaiti market or as a transactional player, which in turn affects access speed and competitive positioning.',
      ],
    },`;

// Expanded market structure for Kuwait
const kuwaitMarketStructureExpanded = `    marketStructure: {
      heading: 'Kuwait market structure for pharmaceutical teams',
      paragraphs: [
        'Kuwait is a smaller but high-value Gulf market: the pharmaceutical sector is forecast to reach about $2.9 billion by 2027, growing around 3.5% a year (BioNixus market analysis, 2024). Healthcare delivery is concentrated in a small number of hospital groups and specialist networks, which simplifies geography but sharpens competition for respondent time and increases the risk that a few key opinion leaders disproportionately influence prescribing patterns. Market research Kuwait samples must be designed with this concentration in mind—over-sampling or over-interpreting outlier opinions can distort market sizing and positioning recommendations.',
        'Chronic disease management and specialty care drive much of the innovative portfolio volume in Kuwait, particularly in cardiology, diabetes, oncology, and immunology. Recruitment plans prioritize the facilities where those patients are managed: MOH referral centers, specialized institutes, and high-volume private hospitals. Geographic spread is less relevant than institutional mix, and market research Kuwait programs validate which accounts represent addressable volume versus which are geographically accessible but clinically out-of-scope.',
        'Cross-border care seeking exists but is less dominant than in UAE; Kuwaiti patients do travel to Saudi Arabia, UAE, or Europe for advanced treatments, but the majority of routine and specialty care remains domestic. This means Kuwait-validated epidemiology and treatment pattern data matter for sizing, and desk research based on regional averages can significantly over- or underestimate market potential. Market research Kuwait fieldwork grounds forecasts in Kuwait-specific physician panel estimates, patient flow data, and prescription volume proxies.',
        'Competitive intelligence in Kuwait focuses on incumbent brands with strong distributor support, medical affairs investment, and historical formulary presence. New entrants face the dual challenge of clinical differentiation and commercial relationship-building; market research Kuwait modules quantify both barriers and identify where messaging, evidence, or partnership strategies can accelerate adoption. Programs compare Kuwait competitive dynamics to <a href="/market-research-egypt">market research Egypt</a> and <a href="/healthcare-market-research/uae">market research UAE</a> to assess whether regional strategies apply or require Kuwait-specific adaptation.',
      ],
    },`;

// Expanded intro for Egypt
const egyptIntroExpanded = `'BioNixus executes market research Egypt engagements for organizations that need evidence-led decisions across public, private, and out-of-pocket channels in North Africa\\'s largest pharmaceutical market. Programs support local manufacturing context, diverse payer behavior, and links to MENA regional strategy. Market research Egypt projects reflect the scale and complexity of a market with over 100 million people, significant generic competition, pricing sensitivity across multiple payer segments, and regional HQ strategic importance for MENA portfolio planning. Egypt\\'s pharmaceutical market—about $6.5 billion in 2024 and projected to roughly double to $13.8 billion by 2033, an 8.74% CAGR (BioNixus market analysis, 2024)—combines mass-market primary care volume with concentrated specialty care in urban centers. That dual reality demands research design that segments by channel, geography, and payer rather than treating Egypt as a monolith. BioNixus designs market research Egypt programs to address this heterogeneity with channel-weighted sampling, Cairo–Alexandria versus governorate splits where relevant, and public-versus-private payer modules that reflect how Egyptian Drug Authority (EDA) registration, tender processes, and Universal Health Insurance Authority (UHIA) policies interact with private hospital formularies and retail pharmacy out-of-pocket purchasing. Our programs link to <a href="/healthcare-market-research/egypt">healthcare market research in Egypt</a>, <a href="/egypt-pharmaceutical-market-research">Egypt pharmaceutical market research companies</a>, and <a href="/blog/top-market-research-companies-egypt-2026">top market research companies in Egypt (2026)</a> to support both primary fieldwork and secondary intelligence needs.',`;

// Expanded regulatory for Egypt
const egyptRegulatoryExpanded = `    regulatory: {
      heading: 'Egypt regulatory and market access context',
      paragraphs: [
        'Egypt market research must account for Egyptian Drug Authority (EDA) requirements, pricing committees, and tender-oriented public procurement alongside private hospital and clinic channels that operate under different economic and competitive logics. EDA registration timelines, bioequivalence expectations for generics, and local manufacturing incentives shape which products can enter Egypt and at what cost structure. Market research Egypt modules validate how physicians perceive imported versus locally manufactured brands, and whether EDA-driven quality or pricing policies affect prescribing or substitution behavior.',
        'Universal Health Insurance Authority (UHIA) expansion and public sector procurement through Ministry of Health tenders create distinct access pathways for hospital-administered and outpatient therapies. Tender cycles, pricing negotiations, and formulary inclusion criteria differ significantly from private hospital purchasing or retail pharmacy dynamics. Market research Egypt studies map which channels matter for your therapy area, what evidence committees require, and how long procurement cycles typically run. Programs quantify the revenue split between public tender volume and private market sales so forecasts reflect realistic channel mix assumptions.',
        'Local manufacturing and generic competition shape willingness to pay and brand loyalty differently than in Gulf markets; studies use Egypt-appropriate analogues and pricing benchmarks rather than importing Saudi or UAE assumptions. Egypt has a large domestic pharmaceutical manufacturing base that produces generics at price points well below imported branded products. Market research Egypt programs test how physicians trade off brand trust versus cost, what clinical or safety concerns justify branded selection, and how private-pay patients versus insured or public sector patients respond to pricing differences. Understanding these dynamics is essential for positioning and pricing strategy in a market where generic substitution is the norm, not the exception.',
        'Economic sensitivity and out-of-pocket spend influence adherence, brand choice, and therapy persistence across chronic disease categories. Market research Egypt modules capture affordability constraints and patient support program design needs where relevant, recognizing that clinical efficacy data alone does not predict real-world uptake when patients cannot afford to fill prescriptions. Programs assess which patient segments can sustain branded therapy costs, where copay assistance or patient support programs are necessary, and how economic barriers affect long-term market sizing assumptions.',
      ],
    },`;

// Expanded market structure for Egypt
const egyptMarketStructureExpanded = `    marketStructure: {
      heading: 'Egypt pharmaceutical market structure',
      paragraphs: [
        'Egypt is North Africa\\'s largest pharmaceutical market — about $6.5 billion in 2024 and projected to roughly double to $13.8 billion by 2033 — an 8.74% CAGR (BioNixus market analysis, 2024). Volume often sits in primary care, retail pharmacy, and chronic disease management, while innovative brands concentrate in urban centers and private hospitals — which is why a single national story can mask very different access realities by channel. Market research Egypt programs segment by geography (Cairo/Alexandria delta versus Upper Egypt governorates), channel (MOH/UHIA tender versus private hospital versus retail), and payer (public insurance versus private insurance versus out-of-pocket) to ensure forecasts reflect where your brand can realistically compete.',
        'Distributor networks and local pharmaceutical company partnerships remain influential; stakeholder maps include commercial operators as well as clinicians. Unlike Gulf markets where pharmaceutical companies often maintain direct market presence, Egypt\\'s market access often depends on distributor relationships, local manufacturing partnerships, or licensing deals with Egyptian pharmaceutical companies. Market research Egypt studies identify which distributors control key hospital and pharmacy networks, what their portfolio strategies are, and how partnership selection affects competitive positioning and margin structure. Programs validate whether direct market entry is feasible or whether partnership is the only viable access route.',
        'Regional HQ teams use Egypt as a scale market for forecasting and as a MENA hub for clinical development, regulatory precedent, and manufacturing partnerships. The scale of Egypt\\'s population and pharmaceutical market makes it a natural anchor for regional strategy, but market research Egypt fieldwork must validate assumptions that desk research alone cannot: physician treatment patterns, patient adherence rates, payer formulary inclusion timelines, and competitive brand performance. Programs prevent the mistake of extrapolating Gulf or European data to Egypt without validating that clinical guidelines, prescribing cultures, and economic realities support those assumptions.',
        'Local manufacturing capacity and government policies favoring domestic production create both opportunity and complexity. Brands willing to partner with local manufacturers or invest in Egyptian production can access preferential pricing, tender qualification, and regulatory pathways not available to purely imported products. Market research Egypt modules quantify how local manufacturing partnerships affect physician and payer perceptions, whether quality concerns exist around local versus imported sourcing, and how these strategic choices influence competitive positioning. Programs assess trade-offs between margin protection and market access speed in a policy environment that increasingly favors localization.',
      ],
    },`;

// Apply Kuwait replacements
content = content.replace(
  /kuwait: \{[\s\S]*?intro:\s*'BioNixus builds market research Kuwait studies[^']*',/,
  (match) => {
    const before = match.substring(0, match.indexOf("intro:") + 6);
    return before + "\n      " + kuwaitIntroExpanded;
  }
);

content = content.replace(
  /(\s+)regulatory: \{[\s\S]*?heading: 'Kuwait regulatory and access context'[\s\S]*?paragraphs: \[[\s\S]*?\],[\s\S]*?\},(\s+marketStructure)/,
  (match, indent, after) => kuwaitRegulatoryExpanded + "\n" + after
);

content = content.replace(
  /(\s+)marketStructure: \{[\s\S]*?heading: 'Kuwait market structure for pharmaceutical teams'[\s\S]*?paragraphs: \[[\s\S]*?\],[\s\S]*?\},(\s+services)/,
  (match, indent, after) => kuwaitMarketStructureExpanded + "\n" + after
);

// Apply Egypt replacements
content = content.replace(
  /egypt: \{[\s\S]*?intro:\s*'BioNixus executes market research Egypt engagements[^']*',/,
  (match) => {
    const before = match.substring(0, match.indexOf("intro:") + 6);
    return before + "\n      " + egyptIntroExpanded;
  }
);

content = content.replace(
  /(\s+)regulatory: \{[\s\S]*?heading: 'Egypt regulatory and market access context'[\s\S]*?paragraphs: \[[\s\S]*?\],[\s\S]*?\},(\s+marketStructure)/,
  (match, indent, after) => egyptRegulatoryExpanded + "\n" + after
);

content = content.replace(
  /(\s+)marketStructure: \{[\s\S]*?heading: 'Egypt pharmaceutical market structure'[\s\S]*?paragraphs: \[[\s\S]*?\],[\s\S]*?\},(\s+services)/,
  (match, indent, after) => egyptMarketStructureExpanded + "\n" + after
);

// Write back
writeFileSync(contentPath, content, 'utf-8');

console.log('✓ Expanded Saudi Arabia content');
console.log('✓ Expanded Kuwait content');
console.log('✓ Expanded Egypt content');
console.log('\nBatch 8 country pages expansion complete. Next: verify word counts.');
